Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

Phase 1

Conditions: Advanced Malignant Tumors

Interventions: Drug: AK104
Drug: AK117
Drug: Paclitaxel
Drug: Capecitabine tablets
Drug: Cisplatin
Drug: Irinotecan
Drug: Oxaliplatin
Drug: Docetaxel
Drug: 5-FU

First Posted Date: 2022-02-11

Last Posted Date: 2022-08-11

Lead Sponsor: Akeso

Target Recruit Count: 130

Registration Number: NCT05235542

Locations: 🇨🇳
Shanghai Renji Hospital, Shanghai, China

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

Phase 1

Conditions: Advanced Malignant Tumors

Interventions: Drug: AK112
Drug: AK117
Drug: Carboplatin
Drug: Cisplatin
Drug: 5-Fluorouracil

First Posted Date: 2022-02-08

Last Posted Date: 2022-05-11

Lead Sponsor: Akeso

Target Recruit Count: 114

Registration Number: NCT05229497

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Phase 2

Active, not recruiting

Conditions: Treatment Related Cancer

Interventions: Drug: 5-FU
Drug: Folinic Acid
Drug: Irinotecan
Drug: Cetuximab
Drug: Avelumab

First Posted Date: 2022-02-01

Last Posted Date: 2023-11-14

Lead Sponsor: Ludwig-Maximilians - University of Munich

Target Recruit Count: 57

Registration Number: NCT05217069

Locations: 🇩🇪
Ludwig Maximilians University, Munich, Germany

A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection

Completed

Conditions: Metastatic Colorectal Cancer
Colorectal Neoplasms

Interventions: Drug: Fluorouracil
Drug: Aflibercept
Drug: Irinotecan

First Posted Date: 2022-01-05

Last Posted Date: 2024-01-22

Lead Sponsor: Sanofi

Target Recruit Count: 140

Registration Number: NCT05178745

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Phase 3

Recruiting

Conditions: Gastric Neoplasms
Gastroesophageal Adenocarcinoma
Esophageal Adenocarcinoma

Interventions: Drug: Trastuzumab
Drug: Zanidatamab
Drug: Capecitabine
Drug: Tislelizumab
Drug: Oxaliplatin
Drug: Cisplatin
Drug: 5-Fluorouracil

First Posted Date: 2021-12-09

Last Posted Date: 2024-11-18

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 918

Registration Number: NCT05152147

Locations: 🇦🇷
Hospital de Gastroenterología Dr Bonorino Udaondo, Buenos Aires, Argentina
🇦🇷
Fundación Centro de Medicina Nuclear y Molecular ER, Córdoba, Argentina
🇦🇷
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

and more 310 locations

Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma

Phase 2

Not yet recruiting

Conditions: Sinonasal Carcinoma

Interventions: Drug: Docetaxel
Drug: Cis Platinum
Drug: 5-FU
Drug: Tazemetostat
Procedure: Surgery
Other: Chemoradiation

First Posted Date: 2021-12-09

Last Posted Date: 2023-02-28

Lead Sponsor: Dr. Victor H.F. Lee

Target Recruit Count: 30

Registration Number: NCT05151588

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Phase 2

Recruiting

Conditions: Anti-PD-1
Neoadjvant Therapy
Oral Squamous Cell Carcinoma
Chemotherapy

Interventions: Drug: Toripalimab (anti-programmed death-1 inhibitor)
Drug: Albumin paclitaxel
Drug: Docetaxel
Drug: Cisplatin
Drug: 5-Fluorouracil

First Posted Date: 2021-11-18

Last Posted Date: 2023-11-22

Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 80

Registration Number: NCT05125055

Locations: 🇨🇳
Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: MK-1084
Biological: Pembrolizumab
Biological: cetuximab
Drug: oxaliplatin
Drug: carboplatin
Drug: leucovorin
Drug: pemetrexed
Drug: 5-fluorouracil

First Posted Date: 2021-10-05

Last Posted Date: 2024-12-02

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 830

Registration Number: NCT05067283

Locations: 🇺🇸
Moffitt Cancer Center ( Site 0261), Tampa, Florida, United States
🇺🇸
START Midwest ( Site 0267), Grand Rapids, Michigan, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0260), Hackensack, New Jersey, United States

and more 63 locations